Dissecting the mechanism of action of the adjuvant system AS01 in human immune cells: synergy of QS-21 and monophosphoryl lipid A and role of type I interferons [PDF]
Frontiers in ImmunologyThe adjuvant system AS01 comprised of the TLR4 agonist monophosphoryl lipid A (MPLA) and the saponin QS-21 embedded in liposomes is currently used in recombinant vaccines against shingles, respiratory syncytial virus infection, and malaria.
Michelle Poe +12 more
doaj +2 more sources
Methodological Issues in Taquet et al.‘s analysis preclude any conclusions regarding AS01 adjuvant’s specific role in dementia prevention [PDF]
npj VaccinesTaquet et al. evaluated the impact of AS01-adjuvanted vaccines on subsequent dementia diagnosis1. The authors conclude: “No difference was observed between the two AS01-adjuvanted vaccines, suggesting that the AS01 adjuvant itself plays a direct role in ...
S. Elizabeth Williams +4 more
doaj +2 more sources
Frontiers in Immunology, 2021 The Adjuvant System AS01 contains monophosphoryl lipid A (MPL) and the saponin QS-21 in a liposomal formulation. AS01 is included in recently developed vaccines against malaria and varicella zoster virus.
Manon Vanheerswynghels +2 more
exaly +3 more sources
Adjuvant system AS01: from mode of action to effective vaccines
Expert Review of VaccinesIntroduction The use of novel adjuvants in human vaccines continues to expand as their contribution to preventing disease in challenging populations and caused by complex pathogens is increasingly understood.
Beatrice Laupeze +2 more
exaly +3 more sources
Comparison of the adjuvant effect of AS01, AS03 and alum on the immune response to GMP-grade H5N1 antigen in guinea pigs [PDF]
Scientific ReportsAdjuvants function as an enhancer and activator of the immune response and can be of pivotal importance for the efficacy of vaccines. AS01, which is a liposome formulation spiked with the saponin derivate QS-21 and the detoxified lipopolysaccharide MPL-A,
Emmelie Eckhardt +7 more
doaj +2 more sources
Human Vaccines and Immunotherapeutics, 2019 A phase III, double-blind, randomized, controlled trial (NCT00866619) in sub-Saharan Africa showed RTS,S/AS01 vaccine efficacy against malaria. We now present in-depth safety results from this study.
Otieno Walter, Seyram Kaali, Lucas TINA
exaly +2 more sources
A platform approach as a plausible option for nonclinical safety assessment of adjuvanted vaccines [PDF]
npj VaccinesVaccine platform technologies are reproducible, standardized manufacturing and development methods that may be leveraged to streamline regulatory approval of new vaccines.
Eric Destexhe
doaj +2 more sources
Human Vaccines and Immunotherapeutics, 2020 Introduction: RTS,S/AS01 is currently the most advanced malaria vaccine but provides incomplete, short-term protection. It was developed for use within the expanded program on immunizations (EPI) for African children. Another use could be adding mass RTS,
Arjen Dondorp +2 more
exaly +2 more sources
Factors contributing to compliance with Expanded Programme on Immunization and RTS, S/AS01 schedules among children aged 24–40 months in Central Tongu District of Ghana [PDF]
Malaria JournalBackground The Expanded Programme on Immunization (EPI) is the most successful global childhood programme in reducing mortality and morbidity from vaccine-preventable diseases.
Diana Sena Awutey-Hinidza +6 more
doaj +2 more sources
PLoS ONE, 2022 BackgroundMalaria morbidity and mortality remain a challenge in Ghana. A promising childhood vaccine is being piloted in Ghana, however with the loss of its low-income status, Ghana is losing associated donor co-funding. User fees have been considered an
Sharon Darkwa +4 more
doaj +3 more sources